Quintana Franco Luis Miguel, González López Raquel, Garde García Héctor, De Palacio Fraguas Andrea, González Enguita Carmen
Department of Urology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Department of Urology, Hospital Central de La Defensa, Madrid, Spain.
Int Urogynecol J. 2024 May;35(5):1021-1026. doi: 10.1007/s00192-024-05767-7. Epub 2024 Mar 23.
Single-incision slings (SIS) have emerged as a less invasive alternative to conventional slings for stress urinary incontinence (SUI) treatment. However, long-term efficacy and safety results remain uncertain owing to a lack of studies.
A retrospective review of 155 patients treated with Altis® for SUI between February 2012 and June 2017, held in 2022, as a continuation of a prospective study in which all patients (197) were reviewed for 2 years after surgery (1, 6, 12, and 24 months). Preoperative demographic data, comorbidities, and pressure-flow studies were also recorded. Continence status and satisfaction rates were assessed using the International Consultation on Incontinence Questionnaire-short form (ICIQ-SF) and the Patient Global Impression of Improvement (PGI-I) respectively. The assessment in the 2022 retrospective review was performed via a telephone survey.
Mean follow-up time after surgery was 85.3 months (82.5-88.1). In 2022, complete continence was present in 75.4% of the patients. The presence of urinary urgency conditioned the ICIQ-SF score (10.9 vs 1.7 points, p < 0.01), with the ICIQ-SF = 0 in 84.5% of the patients with no associated urgency. Satisfaction assessed by the PGI-I was high, with 84.6% of the patients showing improvement. De novo urgency was present in 37,9% of the patients by 2022. Urinary tract infections were the most frequent complication (9.7%), with only 5 documented cases of mesh erosion.
Altis® SIS is a safe and effective device for SUI treatment, with satisfaction rates comparable with those of the conventional slings. Persistence or development of urinary urgency influences the results.
单切口吊带(SIS)已成为治疗压力性尿失禁(SUI)的一种侵入性较小的传统吊带替代方案。然而,由于缺乏研究,其长期疗效和安全性结果仍不确定。
2022年对2012年2月至2017年6月期间接受Altis®治疗SUI的155例患者进行回顾性研究,该研究是一项前瞻性研究的延续,在该前瞻性研究中,对所有患者(197例)术后2年(1、6、12和24个月)进行了复查。还记录了术前人口统计学数据、合并症和压力-流率研究。分别使用国际尿失禁咨询问卷简表(ICIQ-SF)和患者总体改善印象(PGI-I)评估控尿状态和满意率。2022年回顾性研究中的评估通过电话调查进行。
术后平均随访时间为85.3个月(82.5 - 88.1)。2022年,75.4%的患者实现完全控尿。尿急的存在影响ICIQ-SF评分(10.9分对1.7分,p < 0.01),在无相关尿急的患者中,84.5%的患者ICIQ-SF = 0。PGI-I评估的满意度较高,84.6%的患者有改善。到2022年,37.9%的患者出现新发尿急。尿路感染是最常见的并发症(9.7%),仅记录到5例网片侵蚀病例。
Altis® SIS是一种治疗SUI的安全有效装置,满意率与传统吊带相当。尿急持续存在或出现会影响治疗结果。